Wang K, Zeng T, Guo Z, Liang J, Sun S, Ni Y
BMC Infect Dis. 2024; 24(1):1401.
PMID: 39695978
PMC: 11654266.
DOI: 10.1186/s12879-024-10250-1.
Rizvi N, Bibi M, Rana M, Zaffar S, Farooq H
Front Immunol. 2024; 15:1448408.
PMID: 39606247
PMC: 11598339.
DOI: 10.3389/fimmu.2024.1448408.
Gu Z, Song R, Zhang Y, Hao Y, Sheng S, Chen X
Heliyon. 2024; 10(15):e35425.
PMID: 39165927
PMC: 11334814.
DOI: 10.1016/j.heliyon.2024.e35425.
Kumwichar P, Poonsiri C, Botwright S, Sirichumroonwit N, Loharjun B, Thawillarp S
JMIR Public Health Surveill. 2024; 10():e48255.
PMID: 38441923
PMC: 10951833.
DOI: 10.2196/48255.
Karakoc Z, Tascioglu D, Ediz B, Caglan M, Hancer V, Tugrul T
Sisli Etfal Hastan Tıp Bul. 2023; 57(2):216-223.
PMID: 37899804
PMC: 10600628.
DOI: 10.14744/SEMB.2023.48264.
Comparison of Antibody Responses After CoronaVac and BNT162b2 Vaccines in Healthcare Workers.
Oktay Gultekin E, Gultekin O
Indian J Microbiol. 2023; 63(3):361-368.
PMID: 37781011
PMC: 10533450.
DOI: 10.1007/s12088-023-01098-1.
Seroprevalence of SARS-CoV-2 anti-spike IgG antibody among COVID-19 vaccinated individuals residing in Surabaya, East Java, Indonesia.
Megasari N, Yamani L, Juniastuti J, Lusida M, Mori Y
PeerJ. 2023; 11:e16142.
PMID: 37780375
PMC: 10538276.
DOI: 10.7717/peerj.16142.
Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study.
Ates I, Batirel A, Aydin M, Karadag F, Erden A, Kucuksahin O
Vaccines (Basel). 2023; 11(7).
PMID: 37515050
PMC: 10416156.
DOI: 10.3390/vaccines11071234.
Impact of Health Workers' Choice of COVID-19 Vaccine Booster on Immunization Levels in Istanbul, Turkey.
Oren M, Canbaz S, Mese S, Agacfidan A, Demir O, Karaca E
Vaccines (Basel). 2023; 11(5).
PMID: 37243039
PMC: 10223587.
DOI: 10.3390/vaccines11050935.
Comparing T- and B-cell responses to COVID-19 vaccines across varied immune backgrounds.
Cui Z, Luo W, Chen R, Li Y, Wang Z, Liu Y
Signal Transduct Target Ther. 2023; 8(1):179.
PMID: 37142583
PMC: 10157553.
DOI: 10.1038/s41392-023-01422-7.
The effect of the third dose of the BNT162b2 vaccine on anti-SARS-CoV-2 spike antibody levels in healthcare workers with and without COVID-19 infection.
Wolszczak-Biedrzycka B, Bienkowska A, Cieslikiewicz B, Smolinska-Fijolek E, Biedrzycki G, Dorf J
Ann Med. 2023; 55(1):722-732.
PMID: 36820816
PMC: 9970245.
DOI: 10.1080/07853890.2023.2182907.
Homologous booster immunization with an inactivated vaccine induced robust antibody response in healthcare workers: A retrospective study.
Wen G, Zhu M, Li L, Li X, Ye H, Zhou Y
Front Immunol. 2023; 14:1099629.
PMID: 36817474
PMC: 9935570.
DOI: 10.3389/fimmu.2023.1099629.
Evidence synthesis and pooled analysis of vaccine effectiveness for COVID-19 mRNA vaccine BNT162b2 as a heterologous booster after inactivated SARS-CoV-2 virus vaccines.
Kyaw M, Spinardi J, Zhang L, Oh H, Srivastava A
Hum Vaccin Immunother. 2023; 19(1):2165856.
PMID: 36727201
PMC: 9980688.
DOI: 10.1080/21645515.2023.2165856.
Production of a Monoclonal Antibody to the Nucleocapsid Protein of SARS-CoV-2 and Its Application to ELISA-Based Detection Methods with Broad Specificity by Combined Use of Detector Antibodies.
Kim J, Kim D, Baek K, Kim M, Kang B, Maharjan S
Viruses. 2023; 15(1).
PMID: 36680068
PMC: 9866944.
DOI: 10.3390/v15010028.
The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster.
Wolszczak Biedrzycka B, Bienkowska A, Smolinska-Fijolek E, Biedrzycki G, Dorf J
Infect Drug Resist. 2023; 15:7811-7821.
PMID: 36600955
PMC: 9807069.
DOI: 10.2147/IDR.S390351.
Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers.
Tanaka H, Mukai J, Kushibiki K, Mizushima S, Maeda K, Fujimoto Y
Vaccine. 2022; 41(2):365-371.
PMID: 36460533
PMC: 9684125.
DOI: 10.1016/j.vaccine.2022.11.049.
Breakthrough infections, hospital admissions, and mortality after major COVID-19 vaccination profiles: A prospective cohort study.
Wichaidit M, Nopsopon T, Sunan K, Phutrakool P, Ruchikachorn P, Wanvarie D
Lancet Reg Health Southeast Asia. 2022; 8:100106.
PMID: 36349259
PMC: 9633626.
DOI: 10.1016/j.lansea.2022.100106.
Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial.
Omma A, Batirel A, Aydin M, Karadag F, Erden A, Kucuksahin O
Hum Vaccin Immunother. 2022; 18(6):2122503.
PMID: 36315843
PMC: 9746394.
DOI: 10.1080/21645515.2022.2122503.
Phenotypic and functional changes of T cell subsets after CoronaVac vaccination.
Phoksawat W, Nithichanon A, Lerdsamran H, Wongratanacheewin S, Meesing A, Pipattanaboon C
Vaccine. 2022; 40(48):6963-6970.
PMID: 36283898
PMC: 9595408.
DOI: 10.1016/j.vaccine.2022.10.017.
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection.
Chi W, Li Y, Huang H, Chan T, Chow S, Su J
J Biomed Sci. 2022; 29(1):82.
PMID: 36243868
PMC: 9569411.
DOI: 10.1186/s12929-022-00853-8.
